Study follow-up for people who finished the first trial
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This Phase 1 study is a follow-up “rollover” for people who already completed the 12-month visit of an earlier study. It checks what happens next after that prior study and may help doctors understand the ongoing safety and effects of the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign a consent form approved by an ethics review board (IRB) before any study steps start.
- You must have completed the 12-month visit in the earlier study called EXG-US-01.
- You must agree to follow all study instructions and restrictions during the study.
- There are no listed medical exclusion criteria for this rollover study.
- You may need to complete upcoming study procedures as part of the follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term follow-up for people who have already received the investigational drug CLBR001. It aims to monitor their health over time after the treatment.
This trial follows up with people who already received a Century Therapeutics cellular therapy treatment. It mainly checks how you’re doing over time and whether the treatment has lasting effects.
This study follows up on patients with type 1 spinal muscular atrophy (SMA) who already received the EXG001-307 gene therapy in a previous trial. The goal is to monitor their long-term health and safety over time.
This study looks at the long-term health of people who took part in the EXCELLENT trial. If you finished that trial within the last 10 years, you may be able to join this study to help researchers understand how participants are doing over time.
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
This study checks how well a previous early breast cancer treatment works over the long term and monitors safety. It may help you and future patients by providing long-term results from the original trial.
Hear when a new Telomere Biology Disorders With Bone Marrow Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.